Floatz Rating
D27/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
12Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02711345CT.gov A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ltt462 (this asset) | Novartis Pharmaceuticals | P1 | D · 27 |
| Adriamycin | GlaxoSmithKline | P4 | BBB |
| Carboplatin | Eli Lilly and Company | P3 | BB |
| Canfosfamide | Telik | P3 | BB |
| Pazopanib | The Christie NHS Foundation Trust | P2 | BB |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | BB |
| Niraparib | GlaxoSmithKline | P4 | BB |
| Nogitecan | GlaxoSmithKline | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Merck Sharp & Dohme LLC | P3 | B |
+42 more in the Ovarian Neoplasm cohort
Other indications for ltt462
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P2 | C · 33 |
| Colorectal Cancer | — | P1 | D · 27 |
| Non-Small Cell Lung Carcinoma | — | P1 | D · 24 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ltt462 in Ovarian Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ltt462-ovarian-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →